Skip to main content
. Author manuscript; available in PMC: 2021 May 28.
Published in final edited form as: J Med Chem. 2020 May 6;63(10):5501–5525. doi: 10.1021/acs.jmedchem.0c00442

Figure 6A.

Figure 6A.

Treatment of 13a (100 nM) or 13a (100 nM) in combination with p53-MDM2 inhibitor RG7388 (300 nM) and p53 activator Prima-1met (1000 nM) for 24h, respectively. RG7388 can prevent p53 degradation and promote 13a-triggered apoptosis obviously; 6B. Treatment of 13a (200 nM) and 13a (200 nM) in combination with RG7388 (300 nM) for 3h, 6h, 9h, 12h and 24h, respectively. p53 begins to degrade after treatment by 13a for 6h-9h, and the degradation of p53 can be fully recovered by RG7388 within 12h; 6C. Combination Index (CI) for 13a and RG7388 after treatment 0f 24 h. Data was analyzed using CompuSyn Software. CI < 1, = 1, and > 1 indicate synergism, additive effect, and antagonism, respectively.